Identification
- Generic Name
- Saprisartan
- DrugBank Accession Number
- DB01347
- Background
Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure. The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan. It is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism 1.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Saprisartan (DB01347)
- Weight
- Average: 611.431
Monoisotopic: 610.049723164 - Chemical Formula
- C25H22BrF3N4O4S
- Synonyms
- Saprisartan
Pharmacology
- Indication
Saprisartan is used in the treatment of hypertension and heart failure.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
By inhibiting the angiotensin II receptor, this drug leades to a decrease in sodium reabsorption and a decrease in vasoconstriction. This has the combined effect of decreasing blood pressure.
- Mechanism of action
Saprisartan is a selective, potent, orally active and long-acting nonpeptide Angiotensin II type 1 (AT1) receptor antagonist. Saprisartan blocks the renin-angiotensin-aldosterone system (RAAS) at the level of the AT1 receptor that mediates most, if not all, of the important actions of Ang II. Saprisartan binds reversibly to the AT1 receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. AT1 receptor antagonists avoid the nonspecificity of the Ang I converting enzyme (ACE) inhibitors.
Target Actions Organism AType-1 angiotensin II receptor antagonistHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbaloparatide Abaloparatide may increase the hypotensive activities of Saprisartan. Acebutolol Acebutolol may increase the hypotensive activities of Saprisartan. Aceclofenac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saprisartan is combined with Aceclofenac. Acemetacin The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saprisartan is combined with Acemetacin. Acetylsalicylic acid The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saprisartan is combined with Acetylsalicylic acid. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Saprisartan potassium T28707PG7T 146613-90-3 IASZJGRIPLTJMA-UHFFFAOYSA-N
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as 2-arylbenzofuran flavonoids. These are phenylpropanoids containing the 2-phenylbenzofuran moiety.
- Kingdom
- Organic compounds
- Super Class
- Phenylpropanoids and polyketides
- Class
- 2-arylbenzofuran flavonoids
- Sub Class
- Not Available
- Direct Parent
- 2-arylbenzofuran flavonoids
- Alternative Parents
- 2-phenylbenzofurans / Sulfanilides / 1,2,4,5-tetrasubstituted imidazoles / 2-heteroaryl carboxamides / Carbonylimidazoles / Organosulfonamides / Aryl bromides / Organic sulfonamides / N-substituted imidazoles / Aminosulfonyl compounds show 14 more
- Substituents
- 1,2,4,5-tetrasubstituted imidazole / 2-arylbenzofuran flavonoid / 2-heteroaryl carboxamide / 2-phenylbenzofuran / Alkyl fluoride / Alkyl halide / Aminosulfonyl compound / Aromatic heteropolycyclic compound / Aryl bromide / Aryl halide show 35 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- HS64NG1G69
- CAS number
- 146623-69-0
- InChI Key
- DUEWVPTZCSAMNB-UHFFFAOYSA-N
- InChI
- InChI=1S/C25H22BrF3N4O4S/c1-2-19-31-21(14-8-9-14)22(24(30)34)33(19)12-13-7-10-18-16(11-13)20(26)23(37-18)15-5-3-4-6-17(15)32-38(35,36)25(27,28)29/h3-7,10-11,14,32H,2,8-9,12H2,1H3,(H2,30,34)
- IUPAC Name
- 1-({3-bromo-2-[2-(trifluoromethanesulfonamido)phenyl]-1-benzofuran-5-yl}methyl)-4-cyclopropyl-2-ethyl-1H-imidazole-5-carboxamide
- SMILES
- CCC1=NC(C2CC2)=C(N1CC1=CC2=C(OC(=C2Br)C2=CC=CC=C2NS(=O)(=O)C(F)(F)F)C=C1)C(N)=O
References
- General References
- Timmermans PB: Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol. 1999 Nov;15 Suppl F:26F-8F. [Article]
- External Links
- Human Metabolome Database
- HMDB0015437
- PubChem Compound
- 60921
- PubChem Substance
- 46508176
- ChemSpider
- 54892
- ChEMBL
- CHEMBL305544
- ZINC
- ZINC000003919581
- Therapeutic Targets Database
- DAP001257
- PharmGKB
- PA164746338
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0151 mg/mL ALOGPS logP 5.89 ALOGPS logP 3.53 Chemaxon logS -4.6 ALOGPS pKa (Strongest Acidic) 2.27 Chemaxon pKa (Strongest Basic) 4.91 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 120.22 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 137.15 m3·mol-1 Chemaxon Polarizability 54.2 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.647 Caco-2 permeable - 0.6148 P-glycoprotein substrate Substrate 0.5611 P-glycoprotein inhibitor I Non-inhibitor 0.6454 P-glycoprotein inhibitor II Non-inhibitor 0.5279 Renal organic cation transporter Non-inhibitor 0.8625 CYP450 2C9 substrate Non-substrate 0.653 CYP450 2D6 substrate Non-substrate 0.7866 CYP450 3A4 substrate Substrate 0.5105 CYP450 1A2 substrate Non-inhibitor 0.6561 CYP450 2C9 inhibitor Inhibitor 0.6267 CYP450 2D6 inhibitor Non-inhibitor 0.7996 CYP450 2C19 inhibitor Inhibitor 0.5274 CYP450 3A4 inhibitor Non-inhibitor 0.5167 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.8837 Ames test Non AMES toxic 0.5853 Carcinogenicity Non-carcinogens 0.6378 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.5781 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9673 hERG inhibition (predictor II) Inhibitor 0.6568
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 238.841073 predictedDarkChem Lite v0.1.0 [M-H]- 201.50175 predictedDeepCCS 1.0 (2019) [M+H]+ 238.780073 predictedDarkChem Lite v0.1.0 [M+H]+ 203.89732 predictedDeepCCS 1.0 (2019) [M+Na]+ 238.803573 predictedDarkChem Lite v0.1.0 [M+Na]+ 209.76677 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Protein heterodimerization activity
- Specific Function
- Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
- Gene Name
- AGTR1
- Uniprot ID
- P30556
- Uniprot Name
- Type-1 angiotensin II receptor
- Molecular Weight
- 41060.53 Da
References
Drug created at June 30, 2007 18:15 / Updated at February 21, 2021 18:51